Shubham Singh has been a journalist since 2018, covering business and consumer technology for leading media organizations such as India Today, CNBC-TV18, Zee News, and others. As a Reporter for Medtech Insight, he covers policy, regulation, and digital tech. Outside work, Shubham is an avid traveler, foodie, and fitness enthusiast, balancing his schedule with gym sessions, trekking, and OTT binge-watching.
Latest from Shubham Singh
The revival in funding of healthtech and pharma startups was significantly influenced by PharmEasy's $216m funding round, led by the Manipal Education and Medical Group (MEMG), albeit at a reduced valuation of $710m—a sharp decline from its previous $5.6bn valuation in 2021.
The Union Budget 2025 has overlooked several critical aspects that the medical devices and in-vitro diagnostics (IVD) sector had been expecting, industry leaders have pointed out.
Indian Economic Survey 2025: Call for Systematic Pharma, Healthcare Deregulation, Stronger R&D Focus
In addition to deregulation, the Economic Survey 2025 highlights the pressing need for greater innovation and R&D in India’s pharmaceutical industry.
With increased government focus on self-reliance and digital healthcare, 2025 will be a pivotal year for the sector. From startups to established players, all eyes are on the breakthroughs that will define the future of medtech in India.
Indian startups hold significant potential to address the gap created by the ban on import of refurbished medical products, but they face challenges on several fronts and call for more government support.
Healthcare experts believe that India’s ban on imports of refurbished medical devices has left a vacuum and if an implementable policy is not introduced soon, it could prove disastrous for healthcare providers and patients.